Figure 1. TCR-like monoclonal antibody binding to a peptide/MHC complex on a cancer cell. Intracellular tumor-associated antigens (TAAs) are generally processed and presented on the surface of malignant cells in the context of MHC Class I molecules. Highly specific, T-cell receptor (TCR)-like monoclonal antibodies (mAbs) can now be isolated and used to specifically target malignant cells exhibiting specific TAA/MHC complexes on their surface.